Butyrolactone I
(Synonyms: 丁酸内酯I,Olomoucin) 目录号 : GC42997Butyrolactone I是具有口服活性的由A. terreus产生的细胞周期蛋白依赖性激酶1（CDK1）的ATP竞争性抑制剂（在PC-14细胞中对cdc2 激酶的IC50值为20μg/ml）。
Cas No.:87414-49-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Butyrolactone I is an ATP competitive inhibitor of cyclin-dependent kinase 1 (CDK1) with oral activity (the IC50 value of cdc2 kinase in PC-14 cells was 20μg/ml) [1]. CDK is a serine/threonine kinase that forms a complex with cyclins and plays a crucial role in controlling cell division and regulating transcription in response to extracellular and intracellular stimuli [2]. Butyrolactone I has anti-inflammatory, intestinal protection, and anti-tumor effects and can be used in the research of various cancers and non-alcoholic steatohepatitis (NASH) [3-4].
In vitro, pretreatment with Butyrolactone I (10, 20, and 50μM; 24h) can increase the cell proliferation rate of IPEC-J2 cells under heat stress in a dose-dependent manner, and alleviate cell apoptosis by regulating the ROS/PERK/CHOP signaling pathway [5]. Butyrolactone I (63-1000μM; 2h) treatment induces changes in the morphology and spores of A. terreus, increases fungal hyphal branching, reduces the average hyphal growth unit, and enhances the production of secondary metabolites [6].
In vivo, Butyrolactone I (1 and 5mg/kg/day; 14 days) orally administered increased the body weight and colon length of heat-stressed mice, significantly reduced the protein expression of Bax/Bcl-2, and alleviated intestinal oxidative stress and endoplasmic reticulum stress [5]. Butyrolactone I (10-40mg/kg; 8 weeks) orally administered reduced the serum transaminase levels of NASH mice, reduced liver fat accumulation, inhibited inflammation, alleviated oxidative stress, and improved liver fibrosis. Butyrolactone I partially alleviates NASH by inhibiting the NF-κB pathway in signal transduction [7].
References:
[1] Nishio, K., Arioka, H., Kurokawa, H., et al. Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines. Anticancer Res. 16(6B), 3387-3395 (1996).
[2] Wang Q, Bode A M, Zhang T. Targeting CDK1 in cancer: mechanisms and implications[J]. NPJ precision oncology, 2023, 7(1): 58.
[3] Ghfar A A, El-Metwally M M, Shaaban M, et al. Production of terretonin N and butyrolactone I by thermophilic aspergillus terreus TM8 promoted apoptosis and cell death in human prostate and ovarian cancer cells[J]. Molecules, 2021, 26(9): 2816.
[4] Chen S, Zhang Y, Niu X, et al. Coral-derived endophytic fungal product, butyrolactone-I, alleviates LPS induced intestinal epithelial cell inflammatory response through TLR4/NF-κB and MAPK signaling pathways: An in vitro and in vivo studies[J]. Frontiers in Nutrition, 2021, 8: 748118.
[5] Niu X, Chen S, Wang X, et al. Butyrolactone-I from Marine Fungal Metabolites Mitigates Heat-Stress-Induced Apoptosis in IPEC-J2 Cells and Mice Through the ROS/PERK/CHOP Signaling Pathway. Mar Drugs. 2024;22(12):564.
[6] Schimmel TG, Coffman AD, Parsons SJ. Effect of butyrolactone I on the producing fungus, Aspergillus terreus. Appl Environ Microbiol. 1998;64(10):3707-3712.
[7] Tian-Qi C, et al. Butyrolactone I attenuates inflammation in murine NASH by inhibiting the NF-κB signaling pathway. Biochem Biophys Res Commun. 2022 Oct 20;626:167-174.
Butyrolactone I是具有口服活性的由A. terreus产生的细胞周期蛋白依赖性激酶1（CDK1）的ATP竞争性抑制剂（在PC-14细胞中对cdc2 激酶的IC50值为20μg/ml）[1]。CDK是丝氨酸/苏氨酸激酶，与细胞周期蛋白形成复合物，在控制细胞分裂和调节转录以响应细胞外和细胞内刺激中起关键作用 [2]。Butyrolactone I具有抗炎、肠道保护和抗肿瘤作用，可用于各种癌症和非酒精性脂肪肝炎（NASH）的研究 [3]。
在体外，Butyrolactone I（10, 20和50µM; 24h）预处理能够以剂量依赖性方式提高热应激下IPEC-J2细胞的细胞增殖速率，并通过调节ROS/PERK/CHOP信号通路减轻细胞凋亡 [5]。Butyrolactone I（63-1000μM; 2h）处理诱导A. terreus形态和孢子发生变化，增加菌丝分支，减少平均菌丝生长单位，并增强次生代谢产物的产生 [6]。
在体内，Butyrolactone I（1和5mg/kg/day; 14 days）通过口服治疗增加了热应激小鼠的体重和结肠长度，并显著降低Bax/Bcl-2的蛋白表达，同时减轻了肠细胞中的氧化应激和内质网应激 [5]。Butyrolactone I（10-40mg/kg; 8 weeks）通过口服治疗降低了NASH小鼠的血清转氨酶水平，减少肝脏脂肪堆积、抑制炎症、减轻氧化应激，并改善肝纤维化。Butyrolactone I通过抑制信号传导中的NF-κB通路来部分缓解NASH [7]。
| Cell experiment [1]: | |
Cell lines | IPEC-J2 cells |
Preparation Method | IPEC-J2 cells were cultured in DMEM/F12 supplemented with 10% FBS and 1% penicillin/streptomycin at 37°C. After reaching 80% confluence, the following two sets of cells were prepared: one group was subjected to heat shock treatment, and the other group was subjected to Butyrolactone I pretreatment. The heat shock treatment involved placing the cells in a cell incubator at 42°C with 5% CO2 for 1.5h. To assess IPEC-J2 cell viability, a CCK8 assay was performed. Initially, the cells were seeded at a density of 1×104 cells/mL in 96-well plates and treated with varying concentrations of Butyrolactone I (10, 20, and 50µM) for 24h. Afterward, 10µL of CCK-8 solution was added, and the cells were further incubated for 2h. A microplate reader was used to measure cell viability by measuring the absorbance at 450nm. |
Reaction Conditions | 10, 20, and 50µM; 24h |
Applications | Butyrolactone I pretreatment was able to increase the cell proliferation rate of IPEC-J2 cells under heat stress in a dose-dependent manner. |
| Animal experiment [1]: | |
Animal models | C57BL/6J mice |
Preparation Method | Before the experiments commenced, the mice were acclimatized for one week, during which they had unrestricted access to food and water. The mice, exposed to a relative humidity (RH) of 65–85%, were randomly divided into the following five groups (n = 6): the normal control group (−HS) exposed to 24 ± 1°C, the normal control group treated with PBS (0.2mL), the heat stress group (+HS) subjected to 40 ± 1°C for 4h per day, the HS group with a low oral Butyrolactone I concentration (1mg/kg) (L-BTL-I), and the HS group with a high oral Butyrolactone I concentration (5mg/kg) (H-BTL-I). This treatment regimen was continued for 14 days. The mice were subsequently euthanized, and their colons were collected for further research. |
Dosage form | 1, 5mg/kg/day; 14 days; oral |
Applications | Butyrolactone I treatment increased the body weight and colon length of heat-stressed mice, significantly reduced the protein expression of Bax/Bcl-2, and alleviated oxidative stress and endoplasmic reticulum stress in intestinal cells. |
References: | |
| Cas No. | 87414-49-1 | SDF | |
| 别名 | 丁酸内酯I,Olomoucin | ||
| 化学名 | (2R)-2,5-dihydro-4-hydroxy-2-[[4-hydroxy-3-(3-methyl-2-buten-1-yl)phenyl]methyl]-3-(4-hydroxyphenyl)-5-oxo-2-furancarboxylic acid, methyl ester | ||
| Canonical SMILES | O=C1O[C@@](CC2=CC(C/C=C(C)/C)=C(O)C=C2)(C(OC)=O)C(C3=CC=C(O)C=C3)=C1O | ||
| 分子式 | C24H24O7 | 分子量 | 424.5 |
| 溶解度 | DMF: soluble,DMSO: soluble,Ethanol: soluble,Methanol: soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3557 mL | 11.7786 mL | 23.5571 mL |
| 5 mM | 471.1 μL | 2.3557 mL | 4.7114 mL |
| 10 mM | 235.6 μL | 1.1779 mL | 2.3557 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet